The Hidden Liability: Defence Spending and the Veteran ALS Crisis

OTTAWA, Ontario – October 27, 2026 — In the high-stakes theater of federal budgeting, capital allocation reveals a nation’s true priorities. As Canada embarks on a historic expansion of its military capabilities—pledging an additional $8.1 billion over five years to reach ambitious new defence targets—a starkly different kind of strategic imperative arrived on Parliament Hill today. A delegation of more than 40 advocates, clinicians, researchers, and patients is demanding that lawmakers recognize a grim, biological liability of military service.

Their request is precise: a $50-million federal investment over five years into the Canadian Collaboration to Cure ALS. Organized by the ALS Society of Canada, the campaign strategically aligns its funding request with rising national defence spending, framing medical research not as a charitable afterthought, but as a critical component of post-service duty of care.

For strategists analyzing corporate and state governance, the failure to account for long-tail liabilities is a classic operational blind spot. In this context, the liability is the disproportionate rate at which military veterans develop amyotrophic lateral sclerosis (ALS), a rapidly progressive and terminal neurological disease. As the federal government modernizes its fleets and fortifies its ranks, the individuals returning from that service are facing an insidious threat that current health infrastructure is ill-equipped to combat.

The Epidemiology of Service: A Disproportionate Toll

The link between military service and ALS is not a new hypothesis; it is a well-documented epidemiological reality. Decades of peer-reviewed research indicate that veterans are significantly more likely to develop ALS than the general population. While the exact pathophysiological mechanisms remain under investigation, the statistical correlation is undeniable.

A landmark study published in the journal Neurology in July 2026, which analyzed the health records of nearly 9.2 million male U.S. veterans, provided granular insight into this crisis. The data revealed that compared to Army veterans, male veterans of the Air Force had a 29 percent higher rate of ALS. Coast Guard veterans saw a 26 percent higher rate, and Navy veterans a 15 percent higher rate. Furthermore, officers exhibited significantly higher rates of the disease than enlisted personnel—64 percent higher among men and 72 percent higher among women. Researchers hypothesize that this variance may stem from differing occupational exposures, ranging from the high G-forces and vibrations experienced by pilots to prolonged contact with neurotoxic substances, heavy metals, and specialized aviation fuels.

South of the border, the U.S. Department of Veterans Affairs has recognized ALS as a 100 percent service-connected condition since 2008, granting comprehensive benefits regardless of when the diagnosis occurs. In contrast, Veterans Affairs Canada adjudicates disability benefit applications for ALS on a case-by-case basis, evaluating individual medical history and occupational background against prevailing medical theories.

For those living with the disease, the bureaucratic nuances are secondary to the devastating reality of the diagnosis.

“When you serve your country, you accept that there are risks, but I never imagined ALS would be one of the challenges I would face years later,” said Bob Gibson, a retired Royal Canadian Air Force pilot living with ALS. “We need to understand why veterans are at higher risk of developing this disease. I want those answers for my family, for the people serving today, and for future generations. We have an opportunity to invest in the research that can get us there.”

A $50-Million Blueprint for a National Clinical Pipeline

The $50-million request is not merely a plea for generalized research funding; it is a highly structured business plan designed to build an end-to-end clinical pipeline in Canada. The Canadian Collaboration to Cure ALS proposes distributing the funds across four interconnected pillars, effectively creating a national life-sciences infrastructure that could reverse the "brain drain" of top-tier medical researchers and keep cutting-edge clinical trials within Canadian borders.

The first pillar, CAPTURE ALS, is a globally collaborative, pan-Canadian open-science platform. It collects clinical data, imaging, genomics, and biosamples to uncover why the disease affects individuals differently. With federal backing, this platform would expand from four to 12 sites nationwide, driving critical biomarker discovery and establishing Canadian data sovereignty in the neurodegenerative space.

The second pillar is the Canadian Neuromuscular Disease Registry (CNDR), a national database that tracks patients from diagnosis onward. This real-world data is the lifeblood of modern pharmaceutical development. Federal investment would ensure universal enrollment for Canadians with ALS, generating the robust evidence required to negotiate drug access and guide public health policy.

The third and fourth pillars focus on trial execution. The Canadian ALS Research Network (CALS) aims to expand global clinical trial access into rural and remote Canadian communities, democratizing access to experimental therapeutics. Concurrently, Access ALS is designed to build the specialized infrastructure required to attract Phase 1 clinical trials to Canada. Currently, many Canadian patients must travel internationally at immense personal expense to access early-stage experimental treatments. By funding these networks, Canada would not only serve its patients but also position itself as a highly competitive market for global biopharmaceutical investments.

The ROI of Urgent Action

In the context of federal budgeting, a $10-million annual allocation over five years is practically a rounding error. The Department of National Defence's budget for 2024-25 alone is projected at $32.8 billion. Yet, the return on investment for this specific medical funding could be transformative, both economically and socially.

The Canadian Institutes of Health Research (CIHR) operates with an annual budget of approximately $1.3 billion, but navigating its broad mandate often leaves rare and rapidly fatal diseases competing for fragmented grants. The ALS community's request bypasses this slow drip of generalized funding, demanding a targeted injection of capital to stand up a self-sustaining research ecosystem.

“There is simply no time to waste for someone who is living with ALS,” said Tammy Moore, Chief Executive Officer of ALS Canada. “We have incredible researchers across Canada ready to accelerate this work, but they need sustainable federal funding behind them. A $50-million investment over five years is modest in the context of broader federal spending, but it could transform what is possible in ALS research, helping us better understand the disease, build stronger national data, bring more clinical trials to Canada, and give people living with ALS earlier access to potential new therapies.”

The Human Cost of Bureaucratic Delays

Despite the clear economic rationale and the compelling epidemiological data, political momentum remains sluggish. Recent public statements from federal defence officials have indicated a troubling lack of awareness regarding the established link between military service and ALS, highlighting a disconnect between scientific consensus and public policy. While Veterans Affairs Canada points to broader investments in military health research, the lack of a dedicated, disease-specific commitment leaves the ALS community in a precarious holding pattern.

For the nearly 4,000 Canadians currently living with ALS, holding patterns are fatal. Approximately 1,000 Canadians are diagnosed with the disease each year, and four out of five will die within two to five years of that diagnosis. The disease progressively paralyzes its victims, methodically stripping away the ability to walk, talk, eat, swallow, and eventually breathe, while leaving cognitive functions largely intact.

The delegation walking the halls of Parliament Hill today represents a constituency racing against an unforgiving biological clock. Many of the advocates pleading for this $50-million investment know they will not live long enough to see the resulting therapies. Their advocacy is a profound exercise in forward-looking governance, demanding that the state honor its social contract with those who served. As Canada writes the checks to secure its military future, it must decide whether it will also fund the survival of the veterans who wear the uniform.